Search

MannKind Corp

Ouvert

SecteurSoins de santé

3.75

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.73

Max

3.82

Chiffres clés

By Trading Economics

Revenu

-2.4M

-19M

Ventes

19M

109M

P/E

Moyenne du Secteur

140.5

56.597

BPA

-0.06

Marge bénéficiaire

-17.401

Employés

591

EBITDA

10M

13M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+112.93% upside

Dividendes

By Acuity

Prochains Résultats

4 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

131M

1.3B

Ouverture précédente

3.75

Clôture précédente

3.75

Sentiment de l'Actualité

By Acuity

72%

28%

301 / 339 Classement par Healthcare

MannKind Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 sept. 2026, 19:46 UTC

News

MannKind Corp shares are lower today amid broader market trends and inflation data, marking a third consecutive session of declines.

10 sept. 2026, 22:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting notable gains since Thursday's close, though still below the 20-day moving average.

9 sept. 2026, 20:01 UTC

Social Media
News

MannKind Corp shares are lower after announcing a licensing deal with Rose Pharma for the development of ROSE-010, an inhaled GLP-1 receptor agonist.

8 sept. 2026, 20:07 UTC

News

MannKind Corp's shares are higher today amid mixed analyst ratings, including a downgrade from Zacks and a price target increase from Royal Bank of Canada.

4 sept. 2026, 19:36 UTC

MannKind Corp's shares are advancing, recovering from earlier volatility. The stock is currently above its 20-day moving average amid a stable one-month trading range.

3 sept. 2026, 23:26 UTC

MannKind Corp shares are higher in after-market trading, reflecting broader market strength amid reduced rate hike expectations. Major indices reported substantial gains.

1 sept. 2026, 20:08 UTC

MannKind Corp's shares are lower amid a broader market downturn and rising oil prices, which have heightened inflation concerns and interest rate hike expectations.

31 août 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

28 août 2026, 20:07 UTC

MannKind Corp shares are lower today, extending a three-day decline amid rising U.S. Treasury yields and broader equity market concerns.

27 août 2026, 19:46 UTC

MannKind Corp. shares are trading roughly flat, with no specific news identified. The stock remains around the middle of its one-month trading range.

26 août 2026, 20:56 UTC

MannKind Corp shares are higher in after-market trading, reflecting unusual activity. The stock is significantly above its 20-day moving average.

21 août 2026, 19:41 UTC

MannKind Corp. shares are lower today, trading near the lower end of their one-month range while above the 20-day moving average.

20 août 2026, 19:51 UTC

Correlated Moves

MNKD lower today amid declines in the biotechnology sector.

19 août 2026, 23:02 UTC

Correlated Moves

MannKind Corp shares are lower in after-market hours, continuing a downward trend amid broader declines in the biotechnology sector.

18 août 2026, 22:51 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by rising sovereign bond yields.

17 août 2026, 19:46 UTC

News

HC Wainwright lowered Q3 2026 EPS estimates for MannKind Corp to -$0.10 but maintained a “Buy” rating. Shares are higher since Friday's close.

14 août 2026, 19:56 UTC

MannKind Corp. shares are higher today, reversing a four-session decline despite a broader market influenced by a drop in U.S. retail sales.

13 août 2026, 19:01 UTC

MannKind Corp's shares are lower Thursday, continuing a five-day decline amid mixed economic signals and no specific news identified to explain the drop.

12 août 2026, 20:06 UTC

MannKind Corp shares are lower today, continuing a decline since Tuesday's close amid shifting U.S. Treasury yields and broader market uncertainties.

11 août 2026, 23:46 UTC

MannKind shares are higher in after-market trading, reflecting a slight recovery amid a cautious market ahead of the upcoming consumer price index report.

10 août 2026, 22:56 UTC

MannKind Corp shares are higher in after-market hours following Monday's close, though no specific news was identified to explain the price movement.

7 août 2026, 23:01 UTC

MannKind Corp shares declined in after-market trading, reflecting notable weakness despite remaining above the 20-day moving average. No specific news was identified.

6 août 2026, 22:01 UTC

MannKind Corp shares are lower in after-market trading, reflecting broader market weakness and trading below their 20-day moving average. No specific news was identified.

5 août 2026, 23:02 UTC

News

MannKind Corp shares declined after-hours following a second-quarter earnings miss, despite reporting revenues of $109.4 million and FDA approvals for new products.

4 août 2026, 23:26 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

3 août 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 juil. 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 juil. 2026, 18:41 UTC

Event
News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 juil. 2026, 19:47 UTC

News
Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 juil. 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

Comparaison

Variation de prix

MannKind Corp prévision

Objectif de Prix

By TipRanks

112.93% hausse

Prévisions sur 12 Mois

Moyen 7.985 USD  112.93%

Haut 13 USD

Bas 4.16 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

6

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

301 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat